These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38751473)

  • 1. Individualize management for advanced breast cancer with pyrotinib-based anti-HER2 therapy: a case report.
    Xu J; Chen J; Huang P; Zhou H; Wang X; Chen Z
    Transl Breast Cancer Res; 2023; 4():25. PubMed ID: 38751473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
    Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
    Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases.
    Ma X; Li Y; Li L; Gao C; Liu D; Li H; Zhao Z; Zhao B
    Ann Med; 2022 Dec; 54(1):3085-3095. PubMed ID: 36331291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer: a real-world retrospective study in China.
    Liu X; Zhang P; Li C; Song X; Liu Z; Shao W; Li S; Wang X; Yu Z
    Front Oncol; 2023; 13():1136380. PubMed ID: 37404769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathological Complete Response from Pyrotinib Combined with Trastuzumab, Paclitaxel and Cisplatin in a Postpartum Woman with HER2-Positive Locally Advanced Breast Cancer: A Case Report.
    He L; Zhang F; Ma Y; Zuo L; Xu Y
    Onco Targets Ther; 2020; 13():8749-8756. PubMed ID: 32943881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.
    Lin Y; Lin M; Zhang J; Wang B; Tao Z; Du Y; Zhang S; Cao J; Wang L; Hu X
    Cancer Res Treat; 2020 Oct; 52(4):1059-1066. PubMed ID: 32340083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective Analysis of Pyrotinib-Based Therapy for Metastatic Breast Cancer: Promising Efficacy in Combination with Trastuzumab.
    Gu Q; Zhu M; Wang Y; Gu Y
    Breast Cancer (Dove Med Press); 2024; 16():253-268. PubMed ID: 38812479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case Report: Effective Treatment With Pyrotinib and Capecitabine in a Heavily Pretreated Locally Advanced Breast Cancer Harboring Both HER2 Overexpression and Mutant.
    Gao Z; Xu J; Wang Y; Wu J; Sun T
    Front Oncol; 2021; 11():715554. PubMed ID: 34722261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inetetamab combined with pyrotinib and oral vinorelbine for patients with human epidermal growth factor receptor 2 positive advanced breast cancer: A single-arm phase 2 clinical trial.
    Jin N; Xu Y; Wang S; Sun C; Yan X; Yang F; Liang Y; Chen W; Huang X
    Cancer Pathog Ther; 2024 Jan; 2(1):31-37. PubMed ID: 38328709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant pyrotinib plus trastuzumab and vinorelbine for HER2-positive locally advanced breast cancer patient who was initially resistant to HP therapy: a case report and literature review.
    Liu M; Zhou X
    Gland Surg; 2023 Feb; 12(2):317-323. PubMed ID: 36915810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].
    Song GH; Li HP; DI LJ; Yan Y; Jiang HF; Xu L; Wan DG; Li Y; Wang MP; Xiao Y; Zhang RY; Ran R; Wang H
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):254-260. PubMed ID: 32306007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study.
    Li Y; Qiu Y; Li H; Luo T; Li W; Wang H; Shao B; Wang B; Ge R
    Front Oncol; 2021; 11():664429. PubMed ID: 33996589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of HER2-Positive Breast Cancer with Brain Metastases Using Anlotinib and Trastuzumab Deruxtecan: A Case Report.
    Chen Y; Liu C; Wen X; Wang C; He J
    Int J Womens Health; 2024; 16():1277-1283. PubMed ID: 39100110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2-positive metastatic breast cancer with brain metastases responds favorably to pyrotinib and trastuzumab-based treatment: A case report and literature review.
    Chen ML; Yu W; Cui B; Yu Y; Ma Z
    Front Oncol; 2022; 12():980635. PubMed ID: 36741701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significant response to the combination of pyrotinib and letrozole in a patient with metastatic HER2-positive and hormone receptor-positive breast cancer: a case report.
    Li J; Shui Z; Ouyang Q
    Ann Palliat Med; 2021 Sep; 10(9):10124-10129. PubMed ID: 34628933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete response to pyrotinib combined with letrozole as first-line treatment of HER2-positive/HR-positive breast cancer: a case report.
    Xie N; Liu L; Tian C; Hu Z; Ouyang Q
    Ann Transl Med; 2021 Aug; 9(16):1356. PubMed ID: 34532493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inetetamab combined with pyrotinib and chemotherapy in the treatment of breast cancer brain metastasis: A case report.
    Dou QQ; Sun TT; Wang GQ; Tong WB
    World J Clin Cases; 2024 Jan; 12(3):575-581. PubMed ID: 38322469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 + early breast cancer (PHAEDRA).
    Wang C; Zhou Y; Lin Y; Mao F; Guan J; Zhang X; Shen S; Wang X; Zhang Y; Pan B; Zhong Y; Peng L; Cao X; Yao R; Zhou X; Xu C; Xu Y; Sun Q
    BMC Cancer; 2022 Mar; 22(1):269. PubMed ID: 35287613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete response in patient with liver metastasis of HER2-positive breast cancer following therapy with margetuximab: a case report.
    Chang H; Hu T; Hu J; Ding T; Wang Q; Cheng J
    Anticancer Drugs; 2023 Aug; 34(7):883-887. PubMed ID: 36730303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twenty-eight months progression-free survival after pyrotinib therapy for HER2-positive recurrent ovarian clear cell carcinoma: a case report.
    Wu J; You Y; Zhuang R; Guo X; Zhang C; Zhang Q; Zhou Y; Li Q
    Ann Transl Med; 2022 Mar; 10(6):387. PubMed ID: 35433993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.